Effects of quercetin on the bioavailability of doxorubicin in rats: Role of CYP3A4 and P-gp inhibition by quercetin

Archives of Pharmacal Research

Volumn 34, Issue 4, 2011, Pages 607-613

  Choi, Jun Shik ^a   Piao, Yong Ji ^a   Kang, Keon Wook ^a  

^a Chosun University   (South Korea)

Author keywords

Bioavailability; CYP3A4; Doxorubicin; P gp; Pharmacokinetics; Quercetin; Rats

Indexed keywords

CYTOCHROME P450 3A4; DOXORUBICIN; GLYCOPROTEIN P; QUERCETIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; ENZYME ACTIVITY; ENZYME INHIBITION; FIRST PASS EFFECT; IC 50; NONHUMAN; PROTEIN EXPRESSION; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMANS; INJECTIONS, INTRAVENOUS; INSECTS; MALE; P-GLYCOPROTEIN; QUERCETIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79960407129     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-011-0411-x     Document Type: Article

References (30)

1. Andersen, A., Warren, D. J., and Slørdal, L., A sensitive and simple high-performance liquid chromatographic method for the determination of doxorubicin and its metabolites in plasma. Ther. Drug Monit., 15, 455-461 (1993). (Pubitemid 23297251)
2. Avendaño, C. and Menéndez, J. C., Inhibitors of multidrug resistance to antitumor agents (MDR). Curr. Med. Chem., 9, 159-193 (2002). (Pubitemid 34436440)
3. Bogaards, J. J., Bertrand, M., Jackson, P., Oudshoorn, M. J., Weaver, R. J., van Bladeren, P. J., and Walther, B., Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica, 30, 1131-1152 (2000). (Pubitemid 32368013)
4. Cao, X., Gibbs, S. T., Fang, L., Miller, H. A., Landowski, C. P., Shin, H. C., Lennernas, H., Zhong, Y., Amidon, G. L., Yu, L. X., and Sun, D., Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res., 23, 1675-1686 (2006). (Pubitemid 44200529)
5. Choi, J. S., Jo, B. W., and Kim, Y. C., Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur. J. Pharm. Biopharm., 57, 313-318 (2004).
6. Cooray, H. C., Janvilisri, T., van Veen, H. W., Hladky, S. B., and Barrand, M. A., Interaction of the breast cancer resistance protein with plant polyphenols. Biochem. Biophys Res. Commun., 317, 269-275 (2004). (Pubitemid 38401995)
7. Cordon-Cardo, C., O'Brien, J. P., Boccia, J., Casals, D., Bertino, J. R., and Melamed, M. R., Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem., 38, 1277-1287 (1990). (Pubitemid 20266126)
8. Crespi, C. L., Miller, V. P., and Penman, B. W., Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem., 248, 188-190 (1997). (Pubitemid 27218241)
9. Dupuy, J., Larrieu, G., Sutra, J. F., Lespine, A., and Alvinerie, M., Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin. Vet. Parasitol., 112, 337-347 (2003). (Pubitemid 36293674)
10. Fakhoury, M., Litalien, C., Medard, Y., Cavé, H., Ezzahir, N., Peuchmaur, M., and Jacqz-Aigrain, E., Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab. Dispos., 33, 1603-1607 (2005). (Pubitemid 41539956)
11. Ferry, D. R., Smith, A., Malkhandi, J., Fyfe, D. W., deTakats, P. G., Anderson, D., Baker, J., and Kerr, D. J., Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin. Cancer Res., 2, 659-668 (1996). (Pubitemid 26133468)
12. Fojo, A. T., Shen, D. W., Mickley, L. A., Pastan, I., and Gottesman, M. M., Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J. Clin. Oncol., 5, 1922-1927 (1987). (Pubitemid 18010151)
13. Gottesman, M. M., Fojo, T., and Bates, S. E., Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2, 48-58 (2002). (Pubitemid 37328807)
14. Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P., Wolff, T., and Waxman, D. J., Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem., 261, 5051-5060 (1986). (Pubitemid 17204301)
15. Gustafson, D. L., Merz, A. L., and Long, M. E., Pharmaco-kinetics of combined doxorubicin and paclitaxel in mice. Cancer Lett., 220, 161-169 (2005). (Pubitemid 40568773)
16. Hertog, M. G. L., Hollman, P. C. H., and Venema, D. P., Optimization of a quantitative HPLC determination of potentially anticarcinogenic flavonoids in vegetables and fruits. J. Agric. Food Chem., 40, 1591-1598 (1992).
17. Hertog, M. G., Kromhout, D., Aravanis, C., Blackburn, H., Buzina, R., Fidanza, F., Giampaoli, S., Jansen, A., Menotti, A., and Nedeljkovic, S., Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch. Intern. Med., 155, 381-386 (1995).
18. Kaminsky, L. S. and Fasco, M. J., Small intestinal cytochromes P450. Crit. Rev. Toxicol., 21, 407-422 (1991).
19. Kelly, P. A., Wang, H., Napoli, K. L., Kahan, B. D., and Strobel, H. W., Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur. J. Drug Metab. Pharmacokinet., 24, 321-328 (1999). (Pubitemid 30342700)
20. Lamson, D. W. and Brignall, M. S., Antioxidants and cancer. III. Quercetin. Altern. Med. Rev., 5, 196-208 (2000).
21. Lee, H. J. and Lee, M. G., Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. Res. Commun. Mol. Pathol. Pharmacol., 105, 87-96 (1999). (Pubitemid 30395499)
22. Li, X. and Choi, J. S., Effects of quercetin on the pharmacoki-netics of Etoposide after oral or intravenous administration of etoposide in rats. Anticancer Res., 29, 1411-1415 (2009).
23. Merkel, D. E., Fuqua, S. A., Tandom, A. K., Hill, S. M., Buzdar, A. U., and McGuire, W. L., Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression of gene amplification. J. Clin. Oncol., 7, 1129-1136 (1989). (Pubitemid 19196538)
24. Miniscalco, A., Lundahl, J., Regårdh, C. G., Edgar, B., and Eriksson, U. G., Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J. Pharmacol. Exp. Ther., 261, 1195-1199 (1992).
25. Scambia, G., Ranelletti, F. O., Panici, P. B., De Vincenzo, R., Bonanno, G., Ferrandina, G., Piantelli, M., Bussa, S., Rumi, C., and Cianfriglia, M., Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother. Pharmacol., 34, 459-464 (1994). (Pubitemid 24306043)
26. Shin, S. C., Choi, J. S., and Li, X., Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int. J. Pharm., 313, 144-149 (2006).
27. Smylie, M. G., Wong, R., Mihalcioiu, C., Lee, C., and Pouliot, J. F., A phase II, open label, monotherapy study of lipo-somal doxorubicin in patients with metastatic malignant melanoma. Invest. New Drugs, 25, 155-159 (2007). (Pubitemid 46020874)
28. Speth, P. A., van Hoesel, Q. G., and Haanen, C., Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet., 15, 15-31 (1988).
29. van Zanden, J. J., Wortelboer, H. M., Bijlsma, S., Punt, A., Usta, M., Bladeren, P. J., Rietjens, I. M., and Cnubben, N. H., Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem. Pharmacol., 69, 699-708 (2005).
30. Wang, E., Lew, K., Barecki, M., Casciano, C. N., Clement, R. P., and Johnson, W. W., Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem. Res. Toxicol., 14, 1596-1603 (2001). (Pubitemid 34016623)